{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:35:19Z","timestamp":1782776119728,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["RP210027"],"award-info":[{"award-number":["RP210027"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR190079"],"award-info":[{"award-number":["RR190079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA272295"],"award-info":[{"award-number":["P01CA272295"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA302435"],"award-info":[{"award-number":["U54CA302435"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA195568"],"award-info":[{"award-number":["U01CA195568"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:34:35Z","timestamp":1755243275000},"page":"e12-e20.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-4186","authenticated-orcid":false,"given":"Trung Minh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3721-614X","authenticated-orcid":false,"given":"Danielle","family":"Guffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rockbum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun","family":"Oluyomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raka","family":"Bandyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney N.","family":"Miller-Chism","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Udden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha P.","family":"Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Abuasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-2640","authenticated-orcid":false,"given":"Akiva","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima S.","family":"Teegavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-2577","authenticated-orcid":false,"given":"Chijioke","family":"Nze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-2309","authenticated-orcid":false,"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-5110","authenticated-orcid":false,"given":"Jun Yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.08.009_bib0001","unstructured":"SEER*Explorer Application. Surveillance Research Program, National Cancer Institute n.d. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/ (accessed November 19, 2024)."},{"key":"10.1016\/j.clml.2025.08.009_bib0002","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Ca J Clin"},{"key":"10.1016\/j.clml.2025.08.009_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1067289","article-title":"Advances in the treatment of Hodgkin lymphoma: current and future approaches","volume":"13","author":"Ullah","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.08.009_bib0004","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2025.08.009_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2025.08.009_bib0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2019-122406","article-title":"Nivolumab and AVD for early-stage unfavorable Hodgkin lymphoma (NIVAHL)","volume":"134","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.009_bib0007","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41409-022-01599-5","article-title":"Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma","volume":"57","author":"Friend","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.08.009_bib0008","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.08.009_bib0009","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.08.009_bib0010","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2023-188033","article-title":"Utilization and barriers to stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: A \u2018real-world\u2019 Study of treatment patterns and outcomes at a safety-net versus a tertiary academic hospital","volume":"142","author":"Dong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100020","article-title":"Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system","volume":"1","author":"Jiang","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2025.08.009_bib0012","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible: the neighborhood Atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.009_bib0013","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ajh.26623","article-title":"Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations","volume":"97","author":"da Costa","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.009_bib0014","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clml.2025.08.009_bib0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2025.08.009_bib0016","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.009_bib0018","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.009_bib0019","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1055-9965.EPI-13-0865","article-title":"Prevalence of HIV infection among U.S. Hodgkin lymphoma cases","volume":"23","author":"Shiels","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2025.08.009_bib0020","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.009_bib0021","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood.V130.Suppl_1.915.915","article-title":"Survival outcome and insurance status among Hodgkin\u2019s Lymphoma (HL) patients: data from SEER 2007-2014","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.009_bib0022","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/medicina57101026","article-title":"Evaluation of the relapse risk and survival rate in patients with Hodgkin lymphoma: a monocentric experience","volume":"57","author":"Potre","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clml.2025.08.009_bib0023","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","article-title":"Bringing CAR T cell therapy trials to underserved populations","volume":"41","author":"Badr","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.08.009_bib0024","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3109\/10428194.2015.1086919","article-title":"Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma","volume":"57","author":"Brooks","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.clml.2025.08.009_bib0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2025.08.009_bib0026","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial burdens of cancer treatment: a systematic review of risk factors and outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.08.009_bib0027","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12913-024-11129-2","article-title":"Barriers to cancer treatment for people experiencing socioeconomic disadvantage in high-income countries: a scoping review","volume":"24","author":"Bourgeois","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clml.2025.08.009_bib0028","first-page":"11","article-title":"Social determinants of health and cancer survivorship","volume":"7","author":"Coughlin","year":"2021","journal-title":"J Environ Health Sci"},{"key":"10.1016\/j.clml.2025.08.009_bib0029","first-page":"116","article-title":"Helping cancer patients across the care continuum: the navigation program at the Queen\u2019s Medical Center","volume":"72","author":"Allison","year":"2013","journal-title":"Hawaii J Med Public Health"},{"key":"10.1016\/j.clml.2025.08.009_bib0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11912-024-01514-9","article-title":"Patient navigation in cancer treatment: a systematic review","volume":"26","author":"Chen","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2025.08.009_bib0031","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.amjmed.2011.05.020","article-title":"Care of the adult Hodgkin Lymphoma survivor","volume":"124","author":"Thompson","year":"2011","journal-title":"Am J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:15:18Z","timestamp":1772896518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025002861"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}